Tumor POCT - CEA Immunoassay Test Kit
CEA diagnostic test is a proprietary point-of-care fluorescence immunoassay (FIA) designed for prompt and accurate in-vitro quantitative measurement .
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- T/T
- Production method
- OBM
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- diagnostic devices, ivd, poct, fluorescence immunoassay
- Category
- Chemical Reagents & Products
South Korea
| Product name | Tumor POCT - CEA Immunoassay Test Kit | Certification | CE |
|---|---|---|---|
| Category | Chemical Reagents & Products | Material | - |
| Keyword | diagnostic devices , ivd , poct , fluorescence immunoassay | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | 100000 |
| Supply type | OBM | HS code | 3822 |
Product Information
The Optical Q™ CEA diagnostic test is a proprietary point-of-care (POCT) fluorescence immunoassay (FIA) designed for prompt and accurate in-vitro quantitative measurement of CEA.
Carcinoembryonic antigen (CEA) is an oncofetal glycoprotein primarily found in select tissues of a developing baby (fetus). CEA occurs at abnormally high levels in several benign disorders but may also indicate some malignant tumors, including those of the stomach, small intestine, colon, rectum, pancreas, liver, breast, ovary, cervix, and lung. Levels of CEA are significantly lower in colon tissue of adults, but can become elevated when inflammation or tumors arise in any endodermal tissue, including in the gastrointestinal tract, respiratory tract, pancreas and breast.
The Optical Q™ CEA reagent test is used for monitoring the recurrence of cancer.
Specifications
| Working range | 1.0-200.0 ng/mL |
| Reference range | <6 ng/mL |
| CV | <10% |
| Sample type | Serum / Plasma |
| Sample volume | 100 µL |
| Loading volume | 100 µL |
| Assay time | 15 minutes |
| Storage condition | Cartridge: 2-30 °C / Detection buffer: 2-8 °C |
| Shelf life | 24 months |
Ordering Information
| Cat No. | Description | Packing Size | Storage Condition |
| OB152-25 | Optical Q CEA | 25 Test/Box | Cartridge: 2-30℃ Detection Buffer: 2-8℃ |
- Product Info Attached File
-
Optical Q™ COVID Neutralizing Antibody Test Kit_1.pdf
- Verified Certificate
-
B2B Trade
| Price (FOB) | Negotiable | transportation | Air Transportation,Negotiation Other |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | T/T | Shipping time | Negotiable |
- President
- Jeawon Kim, Minyoung Choi
- Address
- Bonbukwan-401, 76, Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Korea
- Product Category
- Other Monitoring & Diagnostic Equipment
- Year Established
- 2019
- Company introduction
-
OptiBio is a South Korean in-vitro diagnostics (IVD) company focused in researching, developing, and manufacturing cutting edge fluorescence immunoassay (FIA) solutions. In 2020, OptiBio was selected by a research fund sponsored by the Bill & Melinda Gates foundation for its unique and dedicated approach to immunoassay.
OptiBio's competitive advantage stems from its strong foundation of experts, each specialized in fields crucial for product development. Our R&D is divided into 3 different teams of scientists and engineers dedicated to the independent development of diagnostic markers, test kits, and analyzers.
Our fundamental approach to in-house specialization allows OptiBio to constantly improve our product performance, customize our solutions based on client feedback, develop new test parameters, and respond to changing market needs.
OptiBio will continue to create, improve, and innovate world-class diagnostic solutions in the field of fluorescence immunoassay and point-of-care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.
- Main Markets
-
Brazil
Ethiopia
Germany
Mexico
Nigeria
- Main Product
- Attached File
